Skip to content
Sample Page
Author:
BioSyent Inc.
Posted Date:
May 19, 2026
BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)
BioSyent Inc.
May 19, 2026
BioSyent Declares Second Quarter 2026 Dividend
BioSyent Inc.
May 14, 2026
BioSyent Releases Financial Results for First Quarter 2026
BioSyent Inc.
May 14, 2026
BioSyent Schedules First Quarter 2026 Earnings Release for May 14, 2026
BioSyent Inc.
May 7, 2026
BioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
BioSyent Inc.
April 15, 2026
FeraMAX is Canada’s Top-Ranked Iron Supplement for 11 Consecutive Years
BioSyent Inc.
April 1, 2026
BioSyent Announces Grant of Restricted Share Units
BioSyent Inc.
March 24, 2026
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
BioSyent Inc.
March 19, 2026
BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
BioSyent Inc.
March 12, 2026
BioSyent Announces Closing of the Acquisition of Oral Science Inc.
BioSyent Inc.
March 2, 2026
1
2
Next
